INDIANAPOLIS--(BUSINESS WIRE)--Esanex, Inc., a clinical stage company developing Heat Shock Protein inhibitors for the treatment of cancer, today announced that it will present data at the 2018 American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago from April 14 – April 18. Data on Esanex’s pre-clinical studies of SNX-2112, the active form of SNX-5422, will be presented in a poster in the Experimental and Molecular Therapeutics track, in session PO.IM02.03 - Immune Mechanisms Invoked by Therapies 1.
Poster Presentation Details:
Title: Transcriptomics analysis of SNX-2112 on immune and
Abstract No: 2758
Poster Board Number: 20
Date/Time: Monday, Apr 16, 2018 1:00 PM - 5:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 33
SNX-5422 is a chemically unique, orally active Hsp90 inhibitor that has provided durable clinical responses in open label trials in non-small cell lung cancer (NSCLC) and neuroendocrine tumors (NET). The potential of SNX-5422 in hematologic cancers is currently being explored in a chronic lymphocytic leukemia (CLL) open label clinical trial (clinicaltrials.gov ID#NCT02973399). With approximately 200 patients treated to date, SNX-5422 has a well-established safety profile that supports studying it in combination with existing approved drugs in a variety of clinical settings.
Esanex is a clinical-stage company with new insights into Heat Shock Proteins as an important cancer target. Our lead program, SNX-5422, has shown durable clinical responses in rationally-designed combination studies in patients with non-small cell lung cancer and neuroendocrine tumors. We are also advancing SNX-5422 in select hematological tumors, including CLL. www.esanexpharma.com